Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 50

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 50
---
 it representative of where such beneficial holders reside, since the shares held in the name of Cede & Co. are listed
for trading on Nasdaq and the TASE and are beneficially owned by a wide range of underlying beneficial shareholders who hold their shares
in “street name,” including Israeli and other non-U. S. shareholders.

B. Related
Party Transactions

Except as described below or elsewhere in this Annual Report, since
January 1, 2024, we have had no transaction, nor do we have any presently proposed transaction, and neither we nor our subsidiaries have
had any loan, nor do we or our subsidiaries have any presently proposed loan, involving any related party described in Item 7. B. of this
Annual Report.

Agreements with Directors and Officers

Employment Agreements

We have entered into written employment agreements with all of
our executive officers. Each of these agreements contains provisions regarding non-competition, confidentiality of information and assignment
of inventions. The non-competition provision applies for a period that is generally 12 months following termination of employment. The
enforceability of covenants not to compete in Israel and in the United States is subject to limitations.

Equity Awards

See “ Item 6. Directors, Senior Management and Employee - B. Compensation - Share
Option and Incentive Plans.”

Indemnification Agreements

Our articles of association allow us to indemnify and insure our
office holders for any liability imposed on them as a consequence of an act which was performed by virtue of being an office holder. They
also allow us to exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of duty of care. In furtherance of such allowance, we have entered into agreements with each of our directors
and executive officers exculpating them, to the fullest extent permitted by law, from liability to us for damages caused to us as a result
of a breach of duty of care, and undertaking to indemnify them to the fullest extent permitted by law. See “ Item 6. Directors, Senior
Management and Employees - C. Board Practices - Exculpation, Insurance and Indemnification of Office Holders.”

Agreement with a Close Family Member of Key Management Personnel

During 2022, we entered into an employment agreement with Mr. Almog
Haviv, the son of our Chief Executive Officer. The